EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer

被引：253

作者：

Horn, Leora ^{[1
]}

Pao, William ^{[1
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 26期

关键词：

GROWTH-FACTOR RECEPTOR; ACTIVATING MUTATIONS; FUSION GENE; ALK KINASE; KRAS MUTATIONS; NEVER SMOKERS; PHASE-III; NPM-ALK; GEFITINIB; IDENTIFICATION;

D O I：

10.1200/JCO.2009.23.6661

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4232 / 4235

页数：4

共 50 条

[41] Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides [J].

Mitiushkina, Natalia V. ;

Iyevleva, Aglaya G. ;

Poltoratskiy, Artiom N. ;

Ivantsov, Alexandr O. ;

Togo, Alexandr V. ;

Polyakov, Igor S. ;

Orlov, Sergey V. ;

Matsko, Dmitry E. ;

Novik, Viktor I. ;

Imyanitov, Evgeny N. .

CANCER CYTOPATHOLOGY, 2013, 121 (07) :370-376

[42] Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer [J].

Garces, Aimie E. ;

Al-Hayali, Mohammed ;

Lee, Jong Bong ;

Li, Jiaxin ;

Gershkovich, Pavel ;

Bradshaw, Tracey D. ;

Stocks, Michael J. .

ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (03) :316-321

[43] Discovery and clinical application of a novel oncogene, EML4-ALK, in lung cancer [J].

Mano, Hiroyuki .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) :S214-S214

[44] Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer [J].

Woo, C. G. ;

Seo, S. ;

Kim, S. W. ;

Jang, S. J. ;

Park, K. S. ;

Song, J. Y. ;

Lee, B. ;

Richards, M. W. ;

Bayliss, R. ;

Lee, D. H. ;

Choi, J. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :791-797

[45] Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing [J].

Moskalev, Evgeny A. ;

Frohnauer, Judith ;

Merkelbach-Bruse, Sabine ;

Schildhaus, Hans-Ulrich ;

Dimmler, Arno ;

Schubert, Thomas ;

Boltze, Carsten ;

Koenig, Helmut ;

Fuchs, Florian ;

Sirbu, Horia ;

Rieker, Ralf J. ;

Agaimy, Abbas ;

Hartmann, Arndt ;

Haller, Florian .

LUNG CANCER, 2014, 84 (03) :215-221

[46] The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer [J].

Lin, Yen-Ting ;

Liu, Yi-Nan ;

Shih, Jin-Yuan .

FRONTIERS IN ONCOLOGY, 2019, 9

[47] Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK-Positive Non-Small-Cell Lung Cancer [J].

Tamiya, Akihiro ;

Okamoto, Isamu ;

Miyazaki, Masaki ;

Shimizu, Shigeki ;

Kitaichi, Masanori ;

Nakagawa, Kazuhiko .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :E15-E17

[48] Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer [J].

Tiseo, Marcello ;

Gelsomino, Francesco ;

Bartolotti, Marco ;

Bordi, Paola ;

Bersanelli, Melissa ;

Rossi, Giulio ;

Ardizzoni, Andrea .

EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (11) :1677-1687

[49] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK [J].

Katayama, Ryohei ;

Khan, Tahsin M. ;

Benes, Cyril ;

Lifshits, Eugene ;

Ebi, Hiromichi ;

Rivera, Victor M. ;

Shakespeare, William C. ;

Iafrate, A. John ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (18) :7535-7540

[50] Membrane Phospholipids, EML4-ALK, and Hsp90 as Novel Targets in Lung Cancer Treatment [J].

Laszlo, Andrei ;

Thotala, Dinesh ;

Hallahan, Dennis E. .

CANCER JOURNAL, 2013, 19 (03) :238-246

← 1 2 3 4 5 →